Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study.

@article{Portenoy2008SubcutaneousMF,
  title={Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study.},
  author={Russell K. Portenoy and Jay J. Thomas and Michele L Moehl Boatwright and Diep Tuan Tran and Frank L. Galasso and Nancy Stambler and Charles F von Gunten and Robert Joseph Israel},
  journal={Journal of pain and symptom management},
  year={2008},
  volume={35 5},
  pages={458-68}
}
Methylnaltrexone, a peripherally-acting quaternary opioid antagonist, is an investigational treatment for opioid-induced constipation in patients with advanced illness. This randomized, parallel-group, repeated dose, dose-ranging trial included a double-blind phase for one week followed by an open-label phase for a maximum of three weeks. Opioid-treated patients with advanced illness who met criteria for opioid-induced constipation despite laxative therapy were potentially eligible. Double… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 49 extracted citations

Methylnaltrexone in the treatment of opioid-induced constipation

Clinical and experimental gastroenterology • 2008
View 3 Excerpts
Highly Influenced

Managing Constipation in Adults With Cancer

Journal of the advanced practitioner in oncology • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…